Endo Health Solutions Inc (NASDAQ:ENDP), a specialty pharmaceutical company will acquire Paladin Labs Inc. (TSE:PLB), which is another specialty drug company located in Canada for $1.6 billion. Paladin products are used in the treatment of allergy, urology, and pain. The acquisition would allow Endo to expand its presence in emerging markets and Canada. Paladin is a natural fit with Endo because essentially both companies do the same thing, production of drugs that reduce pain. The market clearly loves the deal because shares of Endo are up 27 percent.